TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10326217
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of daunorubicin (DNR, 450 mg/m2 in total)
Study: 10326217
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment protocol AL841
Study: 10326217
Drug: Complete remission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete remission (CR) achieved with three-drug induction
Study: 1937073
Drug: Control (fellow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (fellow eye, no treatment)
Study: 31124409
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment involving COMT modulation
Study: 31210343
Drug: Institute of
Normalized name: COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Institute of Medicine (IOM) standards compliance
Study: 31832225
Drug: Delayed-release dimethyl
Normalized name: dimethyl fumarate Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release dimethyl fumarate (DMF)
Study: 23972415
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment-as-usual)
Study: 15347035
Drug: Nimodipine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (90 mg/day during 10 days)
Study: 18559696
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg)
Study: 31900080
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (50,000 IU fortnightly) + Calcium (500 mg daily)
Study: 27225739
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg lornoxicam (Group L)
Study: 27225739
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg paracetamol (Group P)
Study: 24458173
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL water)
Study: 23782587
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg vildagliptin twice daily co-administered with 0.2 mg voglibose three times daily
Study: 16767422
Drug: Tryptophan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan (1 g 3x a day)
Study: 15333400
Drug: Bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 10 mg
Study: 14531252
Drug: Bupivacaine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 12.5 mg
Study: 9570604
Drug: Bupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 15 mg
Study: 14531252
Drug: Tetracaine 10
Normalized name: tetracaine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 10 mg
Study: 17276952
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg daily
Study: 453496
Drug: Etomidate (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (intravenous injection)
Study: 22153012
Drug: Xingnaojing (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing (20 ml/d i.v. drip) + L-carnitine (2 g/d i.v. drip)
Study: 22153012
Drug: Xingnaojing (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing (20 ml/d i.v. drip)
Study: 19826292
Drug: Sublingual ergogenic
Normalized name: ROGENIC TABS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual ergogenic spray containing vitamins, minerals, amino acids, and a coenzyme
Study: 19766760
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (240 ml/day)
Study: 2236581
Drug: Nimodipine 90
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 90 mg administered orally in divided doses for 12 weeks
Study: 29484638
Drug: GDC-0853 (≤600
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0853 (≤600 mg, single ascending dose; ≤250 mg twice daily; ≤500 mg once daily for 14 days)
Study: 29484638
Drug: GDC-0853 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0853 (100 mg, once daily)
Study: 28827417
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg rifampin
Study: 28827417
Drug: rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifampin (600 mg, 900 mg, 1,200 mg)
Study: 20298323
Drug: ICS (fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS (fluticasone propionate) + LABA (salmeterol) (500 mcg/50 mcg bd)
Study: 20298323
Drug: ICS alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS alone (500 mcg bd)
Study: 16176606
Drug: Soya foods
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya foods (two daily servings including tofu, soya milk, soya nuts, and soya protein powder; equivalent to 50 mg isoflavones and 5-22 g soya protein per serving)
Study: 12548322
Drug: Outpatient induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient induction with intravaginal controlled-release prostaglandin-E2 (CR-PGE2)
Study: 7697674
Drug: Diltiazem (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.25 mg/kg)
Study: 17967668
Drug: Esmolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5 mg/kg)
Study: 1846331
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg intravenous timolol
Study: 1846331
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg quinidine pretreatment
Study: 24797376
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose 100 mg IV thrice weekly for up to 2 weeks
Study: 22278344
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (84 mg, 126 mg, and placebo)
Study: 15172090
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg per day)
Study: 3577356
Drug: Trivalent split
Normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent split vaccine (15 micrograms haemagglutinin of A-H3N2, A-H1N1, and B strains)
Study: 3577356
Drug: Booster injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster injection of the same vaccine dosage four weeks after the first immunization
Study: 30712326
Drug: Good psychiatric
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good psychiatric management treatment with the addition of the Motive‐Oriented Therapeutic Relationship
Study: 30712326
Drug: Good psychiatric
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good psychiatric management treatment
Study: 30541217
Drug: Berberine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine (0.4 g, 3 times a day)
Study: 30541217
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only hypoglycemic agents)
Study: 24742381
Drug: mHealth cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth cognitive stimulation therapy (therapist-assisted) for 4 weeks, 2-3 days/week
Study: 24742381
Drug: Control (treatment-as-usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (treatment-as-usual with no neuropsychological intervention)
Study: 10815576
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion programme
Study: 7557599
Drug: Radical surgery
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical surgery without preoperative adjuvant chemotherapy (Control)
Study: 2148321
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of glucosyltransferase (GTF) combined with aluminum phosphate (AP) daily for 5 days.
Study: 7387491
Drug: Bromocriptine mesylate
Normalized name: Bromocriptine Mesylate
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine mesylate (2.5 to 20.0 mg daily)
Study: 31609716
Drug: Trunk‐based vibrotactile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trunk‐based vibrotactile sensory augmentation (SA) during balance exercises
Study: 26893187
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg p.o. once daily for 52 weeks
Study: 22033341
Drug: Buccal envelope
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal envelope flap
Study: 16042664
Drug: Sotalol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol + Telithromycin (800 mg)
Study: 9863281
Drug: Low-dose etretinate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose etretinate combined with eicosapentaenoic acid
Study: 9863281
Drug: Low-dose etretinate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose etretinate alone
Study: 8548058
Drug: Human galanin
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human galanin (hGAL) infusion (80 pmol.kg‐1.min‐1) for 60 minutes
Study: 1978443
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulins (0.4 g/kg body weight IVIG every other week for 26 weeks)
Study: 103182
Drug: 2% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% aqueous solution of sodium cromoglycate
Study: 30683457
Drug: Low-dose colchicine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose colchicine (0.5 mg/day)
Study: 20839670
Drug: Transepithelial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transepithelial treatment (group 1)
Study: 20839670
Drug: Subepithelial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subepithelial treatment (group 2)
Study: 10445773
Drug: Ropivacaine 1%
Normalized name: ROPivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1% with 2% lidocaine and hyaluronidase 15 IU x mL(‐1)
Study: 10445773
Drug: Bupivacaine 0.75%
Normalized name: BUPivacaine 0.75% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.75% with 2% lidocaine and hyaluronidase 15 IU x mL(‐1)
Study: 14657866
Drug: Maternal serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal serum estradiol levels (mean 7.87 nmol/L in asthmatic children)
Study: 14657866
Drug: Maternal serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal serum free estradiol levels (mean 149.5 pmol/L in asthmatic children)
Study: 8210915
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of Adriamycin followed by LAK cells
Study: 3535544
Drug: Gradual tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual tapering of alprazolam
Study: 27628038
Drug: Placebo granules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules, twice daily for 6 months
Study: 22909147
Drug: OLM/AML (dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLM/AML (dual therapy)
Study: 28701487
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone
Study: 19943833
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment with antidepressant medication
Study: 19043609
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of fucose/galactose solution for 21 days
Study: 14616169
Drug: Oral Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Group (intravenous omeprazole plus placebo followed by 7 days of oral omeprazole, clarithromycin and amoxicillin b.d.)
Study: 6189328
Drug: 0.2 mg/1
Normalized name: Dihydrotachysterol 0.2 MG/1 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/1 trioxsalen bath PUVA therapy
Study: 6189328
Drug: equipotent methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: equipotent methoxsalen bath PUVA therapy
Study: 2864945
Drug: Pancuronium bromide
Normalized name: Pancuronium Bromide
DrugBank: Pancuronium (DB01337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pancuronium bromide administered during vecuronium-induced partial neuromuscular blockade
Study: 30659073
Drug: Visit-to-visit variability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visit-to-visit variability (VVV) of fasting blood glucose (FBG) defined as the SD of FBG measurements (≥26.4 mg/dL)
Study: 23138807
Drug: Trial administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial administration
Study: 16467656
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg)
Study: 3519416
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg)
Study: 7514046
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and G-CSF
Study: 25812826
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure Therapy for Adolescents (PE-A)
Study: 10976551
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate (200 mg single oral dose)
Study: 3543073
Drug: Lactate 12%
Normalized name: AMMONIUM LACTATE 12% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate 12% lotion applied twice daily for 4 weeks
Study: 22445938
Drug: Preparation with
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation with polyethylene glycol on the morning of the colonoscopy (study group)
Study: 22445938
Drug: Preparation with
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation with polyethylene glycol on the previous afternoon (control group)
Study: 12033657
Drug: Drug Abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Abuse and Resistance Education (DARE-A)
Study: 10715368
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol in triphasic combination with norgestimate
Study: 2026464
Drug: Level I
Normalized name: BENZOYL PEROXIDE 25 mg in 1 mL TOPICAL GEL [DermaClear Purity Cleanser Level I]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level I T, 150-300 mg (n = 24)
Study: 30612986
Drug: Tapinarof 1%
Normalized name: TAPINAROF 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapinarof 1% twice daily
Study: 1631487
Drug: Chlorhexidine/fluoride gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine/fluoride gel
Study: 6091840
Drug: Intravenous bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bicarbonate (150 mmol)
Study: 28456864
Drug: Engerix B®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix B® (40 μg, 4 doses at 0, 1, 2, and 6 months)
Study: 3142949
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition (PPN)
Study: 24152421
Drug: Increased spacing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased spacing and eventual discontinuation of TNF blockers after 6 months
Study: 18729243
Drug: Garcinia cambogia
Normalized name: Garcinia Cambogia Fruit
DrugBank: Garcinia gummi-gutta fruit (DB14365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garcinia cambogia (2.4 g) plus Amorphophallus konjac (1.5 g)
Study: 17296074
Drug: Promotion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promotion of one's coping resources therapy
Study: 12806521
Drug: Triptans (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptans (various formulations including oral tablets, orally disintegrating tablets, nasal sprays, subcutaneous injections, suppositories)
Study: 4061004
Drug: Adrenaline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 0.5 mg i.v.
Study: 22517217
Drug: Azelnidipine (AZ)
Normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine (AZ) 16 mg
Study: 10966962
Drug: Buffered solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered solution (solution B) - 5 ml 2% lignocaine and 5 ml 0.5% bupivacaine with pH 7.44
Study: 897632
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF)
Study: 23756431
Drug: Anodal transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal transcranial direct current stimulation (A-tDCS) for 10 minutes at 1 mA in the DLPFC, followed by rehabilitative cognitive training, daily for 15 days
Study: 19386430
Drug: Tegafur-uracil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur-uracil (300 mg/m²/d) and leucovorin (75 mg/d) from Days 1 to 19 and from Days 29 to 47, carboplatin (70 mg/m² intravenously for 4 consecutive days), in three cycles every 21 days, with radiotherapy (70 Gy in 35 fractions)
Study: 17332612
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/d)
Study: 16690005
Drug: Venlafaxine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (150 mg/d)
Study: 14624187
Drug: Venlafaxine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (300 mg/d)
Study: 16690005
Drug: Desipramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (100 mg/d)
Study: 16690005
Drug: Nefazodone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (300 mg/d)
Study: 12151999
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg efavirenz
Study: 30987667
Drug: Sipjeondaebo-tang (SDT)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sipjeondaebo-tang (SDT) 3 g three times daily for 8 weeks
Study: 30987667
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 g three times daily for 8 weeks
Study: 27893018
Drug: ω-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 PUFAs (1.4 g daily) plus CBCM
Study: 18813219
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (0.5 mg dutasteride + 0.4 mg tamsulosin once daily)
Study: 18813219
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg once daily)
Study: 22561055
Drug: Oral viscous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral viscous budesonide (OVB)
Study: 30635130
Drug: Betahistine (H3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (H3 receptor inverse agonist)
Study: 30635130
Drug: Thioperamide (H3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioperamide (H3 receptor inverse agonist)
Study: 19466229
Drug: APF gel
Normalized name: APF Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF gel application for 1 min
Study: 19466229
Drug: APF gel
Normalized name: APF Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF gel application for 4 min
Study: 16752874
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil (100 mcg)
Study: 15223097
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of buprenorphine tapered down over 5 days
Study: 11330408
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g of native amylomaize starch, containing 28 g of resistant starch type II
Study: 7044709
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment group
Study: 8387254
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion at 25 pmol/kg/min
Study: 8387254
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion plus placebo inhalation
Study: 8387254
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion plus albuterol inhalation (5 mg)
Study: 8387254
Drug: ANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP infusion (both rates)
Study: 8387254
Drug: ANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP infusion at 25 pmol/kg/min
Study: 22474993
Drug: L-carnitine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine for 2 weeks before ICSI
Study: 8903809
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg meperidine
Study: 3113291
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg butorphanol
Study: 15851889
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg meperidine plus 0.5 mg butorphanol
Study: 10613728
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (IFN) treatment (3 x 10(6), 3 times a week, for 1 year) (n = 30)
Study: 3698513
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (ANG II) infusion for 3 hours
Study: 3698513
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin (AVP) infusion for 3 hours